Skip to main content

Madrigal Pharmaceuticals

Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company headquartered in Conshohocken, Pennsylvania. The company focuses on the development and commercialization of targeted therapeutics for metabolic diseases and liver conditions. Its lead product candidate is resmetirom, a selective thyroid hormone receptor-beta agonist designed to treat non-alcoholic steatohepatitis and liver fibrosis. Revenue is primarily generated from product sales and pharmaceutical licensing or collaborative research agreements. The company serves healthcare providers, hepatology specialists, and patients within metabolic and liver disease markets. Madrigal Pharmaceuticals Inc is publicly traded on the Nasdaq Global Select Market.

8 of the funds FundTelligence covers report a position in Madrigal Pharmaceuticals.

Legal name
Madrigal Pharmaceuticals Inc
Sector
Health Care
Country
United States
Funds holding it
8
Exposure themes
MASH, Metabolic Disease, Obesity & Metabolic Health

Funds holding Madrigal Pharmaceuticals

Loading...